This site is intended for Healthcare professionals only.

Amgen’s Repatha lowers need for cholesterol lowering procedure


Amgen’s Repatha lowers need for cholesterol lowering procedure

Amgen Inc said its injection Repatha significantly reduced the need for patients to undergo a procedure to reduce bad cholesterol, according to the findings of a late-stage study.

The drug, like Regeneron Inc and Sanofi SA’s Praluent, belongs to a class of medicines called PCSK9 inhibitors that were approved on their ability to dramatically lower “bad” LDL cholesterol.

Besides taking drugs, cholesterol patients often undergo a procedure called apheresis, which is as invasive as dialysis and involves using a machine that removes bad cholesterol over a period of between one and three hours, Amgen said.



Source: Reuters
0 comment(s) on Amgen’s Repatha lowers need for cholesterol lowering procedure

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted